M-6223
- Generic Name
- M-6223
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 256
- Registration Number
- NCT05327530
- Locations
- 🇫🇷
Hôpital Henri Mondor - Service d'Oncologie Médicale, Creteil, France
🇫🇷Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical, Le Mans, France
🇫🇷Hopital Caremeau - Service Hématologie Clinique/Oncologie Médicale, Nîmes, France
First in Human Study of M6223
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-12-08
- Target Recruit Count
- 58
- Registration Number
- NCT04457778
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath